# Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

> **NCT05955170** · PHASE2 · RECRUITING · sponsor: **Institut Curie** · enrollment: 66 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Tucatinib in Combination of Oral VP16 and trastuzumab

## Key facts

- **NCT ID:** NCT05955170
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2027-12-19
- **Final completion:** 2028-12-19
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955170, "Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05955170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*